Treatments

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts…

*October 2019*  by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding options for those with progressive disease, explained Timothy F. Burns, MD,…

*October 2018*  by Shalmali Pal Medpage Today and ASCO   Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early 2018 when it was named the "Advance of the Year" in the ASCO Annual Report. Versions of CAR-T cell therapy have shown promise for extending survival in previously incurable forms…

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI)…

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect.  Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These characteristics—which include not only the particular type of…

BiTE antibodies are showing promise as a potential new treatment option for those of us that have progressed on standard of care treatment. What exactly is a BiTE antibody? BiTE is short for "bi-specific T-cell engager," a class of artificial bi-specific monoclonal antibodies that are being investigated for use as…

The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow. https://www.youtube.com/watch?v=GRVMj_AbVOs&feature=youtu.be

*June 2019*  Medscape.  The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events) in some advanced lung cancer patients. Medscape (3/20, Castellino, Subscription Publication) reports a study team “notes that serious iirAEs were seen when osimertinib was given after immunotherapy in six of 41…

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had not received any other treatments first such as conventional chemo. By…